A Phase 2 interventional study of Placebo and Ibuprofen 35 mg in Acute Sore Throat Pain, sponsored by Pierre Fabre Medicament. Completed at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-12.
Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Respiratory Tract Infections with a site in France — 18 open to participants now, 18 under way, 4 of them phase 3. Respiratory Tract Infections · France.
Among the 49 studies in Respiratory Tract Infections with a site in France, this one is the 24th largest by enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2012, is one of 4 in phase 2, and was the 6th registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.
Browse Respiratory Tract Infections studies →18 of the 49 studies in Respiratory Tract Infections with a site in France are open now. Recruiting first, the newest first:
Givaudan France Naturals · Sites in France
Ages 18–65 · Healthy volunteers
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Centre Hospitalier Annecy Genevois · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Grenoble · Sites in France, United States, Germany and 2 more countries
Ages 60+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 1+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 186 is close to the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Median enrollment 301 across the 32 interventional studies, 124 across the 17 observational. Of the 29 that completed or were terminated, 5 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 49 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pierre Fabre Medicament, one of the names counted as Pierre Fabre. Under that name alone:
Pierre Fabre Medicament is the lead sponsor of 73 studies on the registry; 6 are open to participants now.
Pierre Fabre has 3 studies filed under Respiratory Tract Infections — fewer than ten, so there is no comparison to draw.
7 of the studies in Respiratory Tract Infections with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06197152Assistance Publique - Hôpitaux de ParisIdentification and Clinical Validation of Biomarkers Associated With Clinical Severity in Adults Infected With RSV | 2026-12 |
| NCT07787130Givaudan France NaturalsEffect of Immune X on Common Cold Incidence in Healthy Adults | 2027-03-01 |
| NCT07625683Laboratoires ElerteObservational Study of SIROPSEDAL in Acute Cough | 2027-05-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 49 studies in Respiratory Tract Infections with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
"Sore throat is one of the most common complaints encountered in clinical practice. And in 65% of cases, the infection is thought to be viral in nature.
The aim of this study is to evaluate the analgesic profile of 3 Ibuprofen lozenges after single administration in acute sore throat pain."
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Ibuprofen 15 mg
Drug: Ibuprofen 25 mg
Drug: Ibuprofen 35 mg
Positive control
Drug: Strefen
Single administration
Single administration
Single administration
Single administration
Single administration
Change from baseline of Sore Throat Pain Intensity Scale
Time frame: 60 minutes
Change from baseline of Sore Throat Pain relief Scale
Time frame: up to 360 minutes
Change of Sore Throat Pain Intensity Scales
Time frame: up to 360 minutes
Local tolerability examination
Mouth examination including extent of erythema, edema, petechial hemorrhages, ulceration (4 point scale : none, mild, moderate and severe).
Time frame: Baseline (before drug intake) and 360 minutes
General tolerability (reported adverse events)
Time frame: Baseline (before drug intake) and 360 minutes
The record gives a start of Feb 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibuprofen
Respiratory Tract Infections →